Enzolytics Inc (ENZC)

[bigtalan]

How long until we hear they have isolated the sites and will be in trials soon ..

https://www.nature.com/articles/s41467-023-43126-0

A/I answer below
Certainly! Monoclonal antibodies have emerged as a promising avenue for addressing the opioid crisis, particularly in the context of fentanyl. Here’s what we know:

Broadly Neutralizing Antibodies: Scientists at Scripps Research developed experimental antibodies that can block the lethal effects of synthetic opioids, including fentanyl and its potent cousin, carfentanil. These antibodies are referred to as “broadly neutralizing antibodies”. Unlike naloxone, which is commonly used to reverse opioid-related overdoses, these antibodies have a significantly longer half-life, remaining active in the body for more than a week. This extended duration is crucial because carfentanil persists in the body, and renarcotization can occur after an initial dose of naloxone. The Scripps Research antibodies offer a potential route for treating synthetic opioid overdose, either in combination with naloxone or as a stand-alone treatment. Additionally, there are potential applications in national defense, especially given carfentanil’s classification as a chemical terrorist threat1.

How Monoclonal Antibodies Work: Unlike current treatments that displace opioid molecules from receptors in the brain during an ongoing overdose, monoclonal antibodies bind to fentanyl molecules in the bloodstream before they can even reach the brain. This preventive approach could be a game-changer in tackling fentanyl-related deaths2.

FDA Approval for Testing: The Food and Drug Administration (FDA) has granted approval to a North Carolina biotech company to test whether a monoclonal antibody can prevent fentanyl overdoses. This development is critical because fentanyl is becoming a leading cause of death for people under 50. The antibody treatment doesn’t enter the brain, which also limits the risk of addiction3.

Florida’s Deadliest Drug: In Florida, where fentanyl is particularly prevalent, researchers are exploring an antibody treatment that recognizes and binds specifically to fentanyl and its analog molecules. Administered preemptively, this treatment aims to prevent overdoses by intercepting fentanyl in the bloodstream before it reaches the brain4.

In summary, monoclonal antibodies represent a novel and potentially life-saving approach to combat the devastating impact of fentanyl and other synthetic opioids. Their ability to neutralize these dangerous substances could make a significant difference in overdose prevention and treatment.

Learn more:

1. scripps.edu
2. usatoday.com
3. axios.com
4. axios.com